SBI Pharma (India) Manager Performance Evaluation

F0GBR06R8K -- India Fund  

INR 117.37  0.50  0.42%

The entity has beta of 0.0 which indicates the returns on MARKET and SBI Pharma are completely uncorrelated. Although it is extremely important to respect SBI Pharma Reg current price movements, it is better to be realistic regarding the information on equity historical returns. The way of measuring future performance of any fund is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing SBI Pharma Reg technical indicators you can today evaluate if the expected return of 0.0% will be sustainable into the future.

Risk-Adjusted Fund Performance

Over the last 30 days SBI Pharma Reg Gr has generated negative risk-adjusted returns adding no value to fund investors. Despite somewhat strong basic indicators, SBI Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short term losses for the investors.
Fifty Two Week Low109.74
Fifty Two Week High135.50
Annual Report Expense Ratio2.50%
Horizon     30 Days    Login   to change

SBI Pharma Reg Relative Risk vs. Return Landscape

If you would invest  11,737  in SBI Pharma Reg Gr on June 20, 2019 and sell it today you would earn a total of  0.00  from holding SBI Pharma Reg Gr or generate 0.0% return on investment over 30 days. SBI Pharma Reg Gr is generating negative expected returns and assumes 0.0% volatility on return distribution over the 30 days horizon. Simply put, 0% of equities are less volatile than SBI Pharma and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 

SBI Pharma Market Risk Analysis

Sharpe Ratio = 0.0
Good Returns
Average Returns
Small Returns
Based on monthly moving average SBI Pharma is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SBI Pharma by adding it to a well-diversified portfolio.

SBI Pharma Alerts

Equity Alerts and Improvement Suggestions

SBI Pharma Reg is not yet fully synchronised with the market data
The fund retains about 7.41% of its assets under management (AUM) in cash
Additionally see Investing Opportunities. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.